1. Market Research
  2. > Therapy Market Trends
  3. > Cardiovascular Drug Industry
  4. > Cardiovascular Drug Industry Statistics

Cardiovascular Drug Industry Statistics

You might be interested in: Cardiovascular Disease, Pharmaceutical, Diabetes, Hospital, Infectious Disease, Therapy, Anti-Infective, Antidiabetics, Opioid, Analgesic, Statins, Insulin, Hormone, Anesthetics, Salicylic Acid, Lipid Modifying Drug, Anti Rheumatic, Chemotherapy, Antipsychotic, Biguanide.

1-7 of about 100 reports for Cardiovascular Drug

Download Unlimited Documents from Trusted Public Sources

Global Cardiovascular Drug Market

  • January 2016
    27 pages
  • Cardiovascular ...  

    Blood Disease  

    Cardiovascular ...  

  • World  

View report >

Anti-Infective and Cardiovascular Drug Market in the US

  • July 2016
    83 pages
  • Anti-Infective  

    Cardiovascular ...  

  • United States  

View report >

Therapy and Cardiovascular Drug Market in Europe

  • November 2016
    6 pages
  • Therapy  

    Cardiovascular ...  

    ACE Inhibitor  

  • Europe  

View report >

Cardiovascular Drug and Therapy Market in the UK

  • September 2016
    11 pages
  • Cardiovascular ...  

    Therapy  

    Hypertension  

  • United Kingdom  

View report >

Therapy and Cardiovascular Drug Market in India

  • June 2016
    6 pages
  • Anticoagulant  

    Therapy  

    Antiplatelet  

  • India  

View report >

Cardiovascular Drug Market in Australia

  • January 2016
    21 pages
  • Cardiovascular ...  

  • Australia  

View report >

Cardiovascular Drug and Therapy Market in Canada

  • January 2016
    6 pages
  • Cardiovascular ...  

    Therapy  

  • Canada  

View report >
13 reports for Cardiovascular Drug

Purchase Reports From Reputable Market Research Publishers
(From $ 595 - $ 5795)

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 754
  • Industry report
  • Jan 2017
  • by Firstword Pharma

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. ...


ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.